Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective salvage strategies post-CAR T-cell therapy failure. We conducted a multi-institutional retrospective study of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ababneh, Hazim S., Ng, Andrea K., Frigault, Matthew J., Abramson, Jeremy S., Johnson, Patrick Connor, Jacobson, Caron A., Patel, Chirayu G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620597/
https://www.ncbi.nlm.nih.gov/pubmed/37317884
http://dx.doi.org/10.3324/haematol.2023.282804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620597/
https://www.ncbi.nlm.nih.gov/pubmed/37317884
http://dx.doi.org/10.3324/haematol.2023.282804

Ejemplares similares